Solventum reported second-quarter 2026 adjusted earnings per share of $2.55, beating the Zacks Consensus Estimate of $1.91 by 33.5%, and revenues of $2.21 billion, up 2.2% and surpassing the consensus mark of $2.17 billion. The company raised its 2026 organic sales growth guidance to 2.5-3% and adjusted earnings guidance to $7.10-$7.20 per share, up from the prior range of $6.40-$6.60. Solventum also announced its intent to separate its Health Information Systems business to sharpen its MedTech focus. Since the earnings report, shares have added about 11.4%, outperforming the S&P 500, but estimates have been trending downward, and the stock holds a Zacks Rank #3 (Hold).
Solventum Corp.Q2 earnings and revenue beat estimates, and 2026 guidance raised.
Avantor Inc